A team of researchers believe they could bring back the woolly mammoth from extinction within the next two years.

Researchers at the Scripps Research Institute Florida campus have refined the already state-of-the-art gene-editing system CRISPR. The new improvements boost the ability of CRISPR to target, cut and paste genes in human and animal cells and helps to address the concerns of off target gene mutations raised in a recent study [1].
What is CRISPR?
CRISPR is short for “Clustered Regularly Interspaced Short Palindromic Repeat,” and is a gene editing system that exploits an ancient bacterial immune defense process. Some microbes combat viral infection by sequestering a piece of a virus’ foreign genetic material within its own DNA, to serve as a template. The next time the viral sequence is encountered by the microbe, it is detected immediately and cut up for disposal with the help of two types of RNA. Molecules called guide RNAs show the location of the invader, and the CRISPR effector proteins act as the scissors that cut it apart and destroy it.
A ban on human-animal hybrids was just lifted.
ICYMI: A ban on human/animal hybrids has been lifted.
While the middle part of the 20th century saw the world’s superpowers racing to explore space, the first global competition of this century is being set in a much smaller arena: our DNA.
Biomedical engineering has long been a driver of advances in healthcare. From new technologies to diagnose and treat some of the most complex disease to advances that improve quality of life for everyone, the work taking place in labs around the world right now is likely to change the face of healthcare in both the short- and long-term future.
Although there are literally thousands of different projects taking place at this very moment, there are some definite trends taking place in biomedical engineering.
Many rain jackets have zippers at the armpits that, when opened, let out perspiration and funk that would otherwise stay trapped inside. But researchers from the Massachusetts Institute of Technology have created a prototype of a wearable that vents itself automatically in response to sweat—and it does so using bacteria.
Wen Wang, the lead author of a new study about biohybrid wearables in the journal Science Advances, says that the garment with bacteria-triggered vents represents just a stepping stone on their way to creating shirts that do something even better: produce a pleasant smell when you sweat.
To make the prototype garment, the researchers experimented with different structures of latex and bacteria, says Wang, a bioengineer and former research scientist at MIT’s Media Lab and the university’s department of chemical engineering. One such configuration involved just two layers: bacteria on one side, and latex on the other. But what worked best for creating the vented wearable was coating latex on both sides with a type of bacteria called B. subtilis.
Even the most exciting breakthrough medical treatment can be rendered obsolete by a particularly insurmountable obstacle: time.
If a treatment only works temporarily, it has little chance of making a significant difference in the lives of patients, which is why the latest news from the University of Miami’s Diabetes Research Institute is so exciting.
A year after transplanting insulin-producing islet cells into the omentum of a woman with a particularly unwieldy form of type 1 diabetes, the cells continue to operate as hoped.
3D printed ovaries restore fertility to mice. Another step towards more complex organs.
There is a clinical need to develop a bioengineering system to support ovary transplantation. Here, the authors generate a bioprosthetic ovary using 3D printed scaffolds of varying pore architectures to support follicle survival and ovarian function in sterilized mice.
CellAge, the synthetic biology company are going from strength to strength thanks to the support of the community last year during their fundraiser at Lifespan.io.
CellAge is featured in Startup Lithuania. As many of you will recall, CellAge hosted a successful project with us at Lifespan.io and they are busy developing a new aging biomarker for researchers thanks to the support of the community.
Now they are going from strength to strength having just secured a seed round backed by Michael Greve’s Kizoo Technology Capital and other investors.